The Technical Analyst
Select Language :
Kiromic BioPharma, Inc. [KRBP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Kiromic BioPharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Kiromic BioPharma, Inc. is listed at the  Exchange

-9.74% $2.77

America/New_York / 27 mar 2024 @ 14:29


Kiromic BioPharma, Inc.: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 3.57 mill
EPS: -13.35
P/E: -0.210
Earnings Date: Apr 15, 2024
SharesOutstanding: 1.288 mill
Avg Daily Volume: 0.0101 mill
RATING 2024-03-27
B-
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Buy
Return On Asset: Sell
DE: Strong Sell
P/E: Neutral
Price To Book: Strong Sell
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.210 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.04x
Company: PE -0.210 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 2.36 - 3.18

( +/- 14.73%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-18 Catlin Michael Buy 18 000 Restricted Stock Award
2024-03-18 Misajon Pamela Buy 18 000 Restricted Stock Award
2024-03-18 Nagel Michael Buy 18 000 Restricted Stock Award
2023-10-05 Bersani Pietro Buy 65 600 Restricted Stock Units
2023-10-05 Misajon Pamela Buy 7 500 Restricted Stock Units
INSIDER POWER
100.00
Last 47 transactions
Buy: 2 001 102 | Sell: 1 131 551

Forecast: 16:00 - $2.77

Live Trading Signals (every 1 min)

Forecast 1: 14:39 - $2.82
Forecast 2: 15:29 - $2.93
Forecast 3: 16:00 - $2.77
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
Volume Signals
Price $2.77 (-9.74% )
Volume 0.0015 mill
Avg. Vol. 0.0101 mill
% of Avg. Vol 15.26 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Kiromic BioPharma, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Kiromic BioPharma, Inc.

RSI

Last 10 Buy & Sell Signals For KRBP

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Kiromic BioPharma, Inc.

KRBP

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Last 10 Buy Signals

Date Signal @
VTIPMar 28 - 09:36$47.88
IRENMar 28 - 09:36$5.74
LEGNMar 28 - 09:36$56.25
VKTXMar 28 - 09:36$81.10
NFLXMar 28 - 09:35$606.06
AMATMar 28 - 09:35$206.18
CGOUSDMar 28 - 09:3371.04
VCITMar 28 - 09:33$80.44
TLRYMar 28 - 09:32$2.43
MSFTMar 28 - 09:32$419.54

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.